Non Hodgkin Lymphoma Clinical Trial
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.
This study uses a single dose of the investigational product FT596 in the early post-transplant period. Rituximab or an FDA approved by biosimilar including Rituxan®, Truxima®, and Ruxience™ is given 48 to 72 hours prior to FT596. The goal of this study is to 1) establish a maximum tolerated dose (MTD) of FT596 when given 30 days after transplant and 2) to confirm the MTD and safety of giving a single dose of FT596 at Day 7 post-transplant starting at one dose level below the MTD identified at Day 30.
Diagnosis of diffuse large B cell lymphoma or aggressive (high-grade) B-cell lymphoma for which an autologous stem cell transplant is planned or recently completed
High risk for relapse defined as at least one of the below:
Primary induction failure (no complete or partial remission at any point after diagnosis
Initial remission duration < 12 months
Lack of complete metabolic (PET scan) response after 2-3 cycles of salvage chemotherapy
Evidence of c-myc and bcl-2 and/or bcl-6 re-arrangement (double hit or triple hit lymphoma)
Age-adjusted IPI 2-3 at relapse
Age 18 years or older at the time of signing consent.
Agrees to use adequate contraception (or evidence of sterility) for at least 12 months after the last dose of rituximab.
Agrees and signs the separate consent for up to 15 years of follow-up (Long-term Follow-up study CPRC#2020LS052)
Provides voluntary written consent prior to the performance of any research related activities.
Receipt of any investigational therapy within 28 days prior to the first dose of FT596 or planned use of an investigational therapy during the first 100 days after transplant
Planned post-transplant irradiation prior to Day +100
Seropositive for HIV, active Hepatitis B or C infection with detectable viral load by PCR
Body weight <50kg
Known allergy to the following FT596 components: albumin (human) or DMSO
Unable to receive rituximab
Post-HSCT Reconfirmation of eligibility
No life-threatening medical issues (i.e. ongoing Grade 4 adverse events) where, in the opinion of the treating investigator, use of FT596 is not in the patient's best interest.
No active uncontrolled infection.
Adequate organ function post-transplant including:
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 x ULN (Grade 2 CTCAE v5)
total bilirubin ≤1.5 x ULN (Grade 1 CTCAE v5)
serum creatinine ≤1.5 x ULN (Grade 1 CTCAE v5)
oxygen saturation ≥93% on room air
For Day 30 dosing only - CBC requirement consistent with engraftment (ANC>500, platelet>20,000 without transfusion support within previous 7 days). There are no CBC parameters for Day 7 dosing.
No requirement for systemic immunosuppressive therapy (> 5mg prednisone daily) during the FT596 dosing period.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Minneapolis Minnesota, 55401, United States
Saint Louis Missouri, 63110, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.